BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Delhove JMKM, Qasim W. Genome-Edited T Cell Therapies. Curr Stem Cell Rep 2017;3:124-36. [PMID: 28596938 DOI: 10.1007/s40778-017-0077-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Pavelic K, Pavelic SK. Genomic Editing, Human Enhancement, and Transhumanism: A Brief Overview. Donald School Journal of Ultrasound in Obstetrics and Gynecology 2022;16:210-221. [DOI: 10.5005/jp-journals-10009-1934] [Reference Citation Analysis]
2 Murty T, Mackall CL. Gene editing to enhance the efficacy of cancer cell therapies. Mol Ther 2021;29:3153-62. [PMID: 34673274 DOI: 10.1016/j.ymthe.2021.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Hakakzadeh Z, Yekehfallah V, Ebrahimiyan H, Sayadmanesh A, Basiri M. Application of Genome-Editing Technologies for Off-the-Shelf T Cell-Based Cancer Immunotherapy. Precis Med Clin OMICS 2021;1. [DOI: 10.5812/pmco.116796] [Reference Citation Analysis]
4 Britten CM, Shalabi A, Hoos A. Industrializing engineered autologous T cells as medicines for solid tumours. Nat Rev Drug Discov 2021;20:476-88. [PMID: 33833444 DOI: 10.1038/s41573-021-00175-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Greenfield A. Making sense of heritable human genome editing: Scientific and ethical considerations. Prog Mol Biol Transl Sci 2021;182:1-28. [PMID: 34175039 DOI: 10.1016/bs.pmbts.2020.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pande A, Bhat RAH, Saxena A, Tyagi M. Concepts and potential applications of gene editing in aquaculture. Genomics and Biotechnological Advances in Veterinary, Poultry, and Fisheries 2020. [DOI: 10.1016/b978-0-12-816352-8.00011-4] [Reference Citation Analysis]
7 Sgodda S, Cantz T. Editierung induzierter pluripotenter Stammzellen mittels CRISPR/Cas9. Biospektrum 2018;24:707-708. [DOI: 10.1007/s12268-018-0984-8] [Reference Citation Analysis]
8 Greenfield A. Carry on editing. Br Med Bull 2018;127:23-31. [PMID: 30202929 DOI: 10.1093/bmb/ldy020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Barzel A. Immune Gene Therapy and the International Conference on Lymphocyte Engineering (ICLE 2018). Hum Gene Ther 2018;29:vii-ix. [PMID: 29902085 DOI: 10.1089/hum.2018.29069.aba] [Reference Citation Analysis]
10 Smith M, Zakrzewski J, James S, Sadelain M. Posttransplant chimeric antigen receptor therapy. Blood 2018;131:1045-52. [PMID: 29358181 DOI: 10.1182/blood-2017-08-752121] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 10.4] [Reference Citation Analysis]
11 Zhu X, Cai H, Zhao L, Ning L, Lang J. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget 2017;8:64607-21. [PMID: 28969098 DOI: 10.18632/oncotarget.19929] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]